Using RYZ811 and RYZ801 to identify and treat patients with advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional study evaluates the theranostic pair RYZ811, a diagnostic agent, and RYZ801, a therapeutic agent, in patients with GPC3+ unresectable hepatocellular carcinoma (HCC). The study aims to identify suitable candidates for treatment and assess the safety and efficacy of these agents. Participants will be monitored for measurable disease progression and response to the therapy. The study is designed to provide insights into the potential benefits of this novel approach in managing advanced liver cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age of at least 18 years at the time of signing the informed consent form (ICF)
* Histologically/cytologically confirmed diagnosis of HCC.
* Barcelona Clinic Liver Cancer (BCLC) Stage C or BCLC Stage B not amenable to locoregional therapy
* Child-Pugh A
* Eastern Cooperative Oncology Group (ECOG) performance status (PS 0-1)
* Disease progression after 1 prior systemic therapy for unresectable HCC
* Measurable disease per RECIST v1.1
* Sufficient renal function
* Adequate hematologic function
* Adequate hepatic function
* The subject must have recovered from toxicities related to prior treatments to ≤Grade 1, unless clinically nonsignificant and/or stable on supportive therapy
* If HBV or HCV infection: Disease managed per local practice; antiviral treatment is allowed.
* Gastric or esophageal varices previously treated with endoscopic therapy according to institutional standards are permitted if no clinically significant bleeding
* For women of childbearing potential (WOCBP):

  * Negative serum pregnancy test within 48 hours prior to the first dose of RYZ811
  * Agreement to use barrier contraception and a second form of highly effective contraception
* For sexually active males:

  * Must use a condom during intercourse
  * Male subjects whose sexual partners are WOCBP must also agree to use a second form of highly effective contraception
  * A condom is required to be used also by vasectomized men

Exclusion Criteria:

* Subjects with fibrolamellar carcinoma, sarcomatoid HCC or combined hepatocellular cholangiocarcinoma
* Prior liver transplantation
* Known hypersensitivity to 68Ga, 225Ac or any of the excipients of RYZ811 or RYZ801
* Portal vein tumor thrombosis classified as Vp4
* Documented hepatic encephalopathy within 6 months of enrollment
* Clinically meaningful ascites within 6 months of enrollment
* Prior EBRT to the liver within 12 weeks prior to receiving RYZ811
* Prior liver radioembolization
* Previously treated central nervous system (CNS) metastasis without recovery from acute side effects
* Documented history of idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD) or pneumonitis
* Uncontrolled significant intercurrent illness including, but not limited to:

  * QT interval corrected for heart rate using Fridericia's formula (QTcF) \>470 ms
  * Hemoglobin A1c (Hgb A1c) ≥8%
  * Uncontrolled hypertension
  * Dose Expansion only: Prior treatment with lenvatinib is exclusionary
  * Significant cardiovascular disease or heart failure
* History of clinically significant bleeding
* Prior participation in any interventional clinical study
* Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
* Have a history of primary malignancy within the past 3 years other than (1) HCC, (2) adequately treated carcinoma in situ or non-melanoma carcinoma of the skin, (3) any other curatively treated malignancy that is not expected to require treatment for recurrence during participation in the study, or (4) an untreated cancer on active surveillance that may not affect the subject's survival status for \>3 years
* Subject requires other treatment that in the opinion of the Investigator would be more appropriate than what is offered in the study
* Pregnancy or breastfeeding

Note: Additional criteria may apply and will be assessed by the study site

Where it's running

• Research Facility
  Birmingham, Alabama, United States Recruiting
• Research Facility
  Phoenix, Arizona, United States Recruiting
• Research Facility
  Orange, California, United States Recruiting
• Research Facility
  Jacksonville, Florida, United States Recruiting
• Research Facility
  Lexington, Kentucky, United States Recruiting
• Research Facility
  Baltimore, Maryland, United States Recruiting

Study contacts

• Study coordinator: RayzeBio Clinical Trials
• Email: clinicaltrials@rayzebio.com
• Phone: 1-619-657-0057

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• AI-guided treatment choices for advanced liver cancer

  Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.

  Recruiting at 5 sites Universitaire Ziekenhuizen KU Leuven · Anderlecht and 4 other locations · NCT07863258

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Biomarker testing to predict treatment response and recurrence in liver cancer

  This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07840092

• MRI plus diffusion and CEST imaging to map liver cancer and its immune environment

  This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07838415

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.